Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.

Autor: Kopec AK; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Yokokawa R; Department of Micro Engineering, Kyoto University, Japan., Khan N; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Horii I; Drug Safety Research & Development, Pfizer, Inc., Japan., Finley JE; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Bono CP; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Donovan C; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Roy J; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Harney J; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Burdick AD; Drug Safety Research & Development, Pfizer, Inc., MA, USA., Jessen B; Drug Safety Research & Development, Pfizer, Inc., CA, USA., Lu S; Drug Safety Research & Development, Pfizer, Inc., CA, USA., Collinge M; Drug Safety Research & Development, Pfizer, Inc., CT, USA., Sadeghian RB; Department of Micro Engineering, Kyoto University, Japan., Derzi M; Drug Safety Research & Development, Pfizer, Inc., MA, USA., Tomlinson L; Drug Safety Research & Development, Pfizer, Inc., MA, USA., Burkhardt JE; Drug Safety Research & Development, Pfizer, Inc., CT, USA.

Publikováno v: The Journal of toxicological sciences [J Toxicol Sci] 2021; Vol. 46 (3), pp. 99-114.

Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.

Autor: Trujillo JI; Departments of Medicinal Chemistry, Pfizer Global Research and Development, Chesterfield, MO 63017, United States. john.i.trujillo@pfizer.com, Kiefer JR, Huang W, Day JE, Moon J, Jerome GM, Bono CP, Kornmeier CM, Williams ML, Kuhn C, Rennie GR, Wynn TA, Carron CP, Thorarensen A

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Jun 01; Vol. 22 (11), pp. 3795-9. Date of Electronic Publication: 2012 Apr 13.

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

Autor: Carron CP; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Trujillo JI; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Olson KL; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Huang W; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Hamper BC; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Dice T; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Neal BE; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Pelc MJ; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Day JE; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Rohrer DC; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Kiefer JR; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Moon JB; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Schweitzer BA; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Blake TD; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Turner SR; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Woerndle R; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Case BL; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Bono CP; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Dilworth VM; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Funckes-Shippy CL; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Hood BL; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Jerome GM; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Kornmeier CM; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Radabaugh MR; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Williams ML; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Davies MS; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Wegner CD; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Welsch DJ; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Abraham WM; Department of Research, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, Florida 33140., Warren CJ; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Dowty ME; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Hua F; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Zutshi A; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Yang JZ; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017., Thorarensen A; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2010 Feb 02; Vol. 1 (2), pp. 59-63. Date of Electronic Publication: 2010 Feb 02 (Print Publication: 2010).

Characterization of dendritic cells generated in vivo by an E. coli derived chimeric dual receptor agonist.

Autor: Kahn LE; Pharmacia Corporation, St. Louis, Missouri, USA. larry.e.kahn@pharmacia.com, Doshi PD, McGarity KL, Yu M, Bono CP, Lie WR, Rankin AM, Smidt ML, Streeter PR, Klein BK, Welply JK, Woulfe SL

Publikováno v: Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2002 Dec; Vol. 8 (12), pp. BR504-14.

Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1*0401.

Autor: Woulfe SL; Searle/Monsanto Co., St. Louis, MO 63198, USA., Bono CP, Zacheis ML, Kirschmann DA, Baudino TA, Swearingen C, Karr RW, Schwartz BD

Publikováno v: Arthritis and rheumatism [Arthritis Rheum] 1995 Dec; Vol. 38 (12), pp. 1744-53.